Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.

EBioMedicine - 1 May 2023

Ip Jonathan Daniel, Wing-Ho Chu Allen, Chan Wan-Mui, Cheuk-Ying Leung Rhoda, Umer Abdullah Syed Muhammad, Sun Yanni, Kai-Wang To Kelvin

Abstract excerpt

BACKGROUND: Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CLpro) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CLpro mutations that are associated with reduced susceptibility to these antivirals. The aim of the current study was to estimate the global prevalence of 3CLpro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endopeptidases

Share to Mutation

Share to Peptide Hydrolases

Share to Prevalence

Share to Ritonavir

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 37060743
DOI: 10.1016/j.ebiom.2023.104559
PMCID: PMC10101811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.PMID 37060743Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read ↗

Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.Semantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain ResistanceSemantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.